Open access · CC-BY
via OpenAlex
Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease
Giorgio Turconi, Farhan Alam, Tanima SenGupta, Sini Pirnes-Karhu, Soophie Olfat, Mark S. Schmidt, Kärt Mätlik, Ana Montaño-Rodriguez, Vladimir Heiskanen, Daniel R. Garton, Petteri T. Piepponen, Charles Brenner, Carina I. Holmberg, Hilde Loge Nilsen, Eija Pirinen
Heliyon · 2024 · ▲ 7 citations
Abstract
Parkinson's disease (PD) is associated with a reduction in 26/20S proteasome and mitochondrial function and depletion of dopamine. Activation of mitochondrial function with the NAD + precursor nicotinamide riboside (NR) is a potential therapeutic for PD. However, despite recently started clinical trials, analysis of NR in mammalian animal PD models is lacking and data in simpler PD models is limited. We analyzed the effect of NR in C. elegans and in mouse 26/20S proteasome inhibition models of PD. In C. elegans , NR rescued α-synuclein overexpression induced phenotypes likely by activating the mitochondrial unfolded protein response. However, in a proteasome inhibitor-induced mouse model of PD, NR first partially rescued behavioural dysfunction, but later resulted in decrease in dopamine and its related gene expression in the substantia nigra. Our results suggest that reduction in 26/20S function with long term NR treatment may increase risk for developing reduced nigrostriatal DA function.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.heliyon.2024.e34355
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Turconi, G., Alam, F., SenGupta, T., Pirnes-Karhu, S., Olfat, S., Schmidt, M.S., Mätlik, K., Montaño-Rodriguez, A., Heiskanen, V., Garton, D.R., Piepponen, P.T., Brenner, C., Holmberg, C.I., Nilsen, H.L., Pirinen, E., & Andressoo, J. (2024). Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease. <em>Heliyon</em>. https://doi.org/10.1016/j.heliyon.2024.e34355
Vancouver
Turconi G, Alam F, SenGupta T, Pirnes-Karhu S, Olfat S, Schmidt MS, et al. Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease. Heliyon. 2024. doi:10.1016/j.heliyon.2024.e34355.
BibTeX
@article{giorgio2024Nicoti,
title = {Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease},
author = {Giorgio Turconi and Farhan Alam and Tanima SenGupta and Sini Pirnes-Karhu and Soophie Olfat and Mark S. Schmidt and Kärt Mätlik and Ana Montaño-Rodriguez and Vladimir Heiskanen and Daniel R. Garton and Petteri T. Piepponen and Charles Brenner and Carina I. Holmberg and Hilde Loge Nilsen and Eija Pirinen and Jaan‐Olle Andressoo},
journal = {Heliyon},
year = {2024},
doi = {10.1016/j.heliyon.2024.e34355},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2021
Preprint · CC-BY
Nicotinamide riboside alleviates Parkinson’s disease symptoms but downregulates dopamine metabolism upon lactacystin-induced proteostasis failure
International Journal of Molecular Sciences 2022
Open access · CC-BY
Nicotinamide Mononucleotide Supplementation Improves Mitochondrial Dysfunction and Rescues Cellular Senescence by NAD+/Sirt3 Pathway in Mesenchymal Stem Cells
Experimental Neurology 2009
Citation only
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease
Aging Cell 2021
Open access · CC-BY
NAD + supplementation prevents STING‐induced senescence in ataxia telangiectasia by improving mitophagy
Current Hypertension Reports 2022
Preprint · OA
Mitochondrial Dysfunction in the Pathogenesis of Preeclampsia
Aging Cell 2021
Open access · CC-BY